Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old. (SHOview)
SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
-
Aix En Provence, Frankrig
- Cabinet Mirabeau Roy René (there may be other sites in this country)
-
Angers, Frankrig
- Hôtel Dieu
-
Beaumont, Frankrig
- Clinique la Chataigneraie
-
Bordeaux, Frankrig
- CHU Pellegrin
-
Chambray les tours, Frankrig
- Clinique Leonard de Vinci
-
Créteil, Frankrig
- CHI
-
Dreux, Frankrig
- Hôpital Victor Jousselin
-
Ecully, Frankrig
- Institut Rhonalpin
-
Grenoble, Frankrig
- Cabinet Médical Maréchal Leclerc
-
Le Havre, Frankrig
- Groupe Hospitalier du Havre - Hôpital Jacques Monod
-
Lille, Frankrig
- Hôpital Jeanne de Flandre
-
Lille, Frankrig
- Cabinet Médical Lille avenue de Dunkerque
-
Lyon, Frankrig
- Hôpital Privé Natecia
-
Marseille, Frankrig
- CHU de Marseille -Hôpital Conception
-
Metz, Frankrig
- Hôpital Maternité de Metz
-
Nantes, Frankrig
- CHU de Nantes
-
Paris, Frankrig
- Hôpital St Vincent de Paul
-
Paris, Frankrig
- Cabinet Médical de Prony
-
Rennes, Frankrig
- CHU de Rennes
-
Rennes, Frankrig
- Clinique Mutualiste La Sagesse
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Women who present infertility of more than one year and are candidates for a first or second IVF cycle with or without ICSI for whom HP-hMG is prescribed for COS.
- Absence of infertility treatment during the last 3 months before enrolment.
- Age: from 18 to 36 years old.
- BMI between 18 and 30 kg / m².
- Presence of both ovaries accessible to puncture and absence of ovarian or uterine abnormalities.
- Male or female infertility.
- Ovarian stimulation by HP-hMG with pituitary desensitization by a GnRH agonist or antagonist.
- Normal ovarian reserve according to physician habitual evaluation.
- Consent to participate of the no-interventional study and signature of the patients' information sheet.
Exclusion Criteria:
- Presence of a chronic disease, cancer or endocrine disease that could potentially influence the results of the stimulation or that represents a contraindication for ovarian stimulation.
- Known endometriosis grade III or IV.
- Contraindication to the use of gonadotropins or current pregnancy diagnosed by the clinician.
- Recurrent miscarriages, known genetic disease of one of the partners or indication of a preimplantation genetic diagnosis (PGD).
- Smoking over than 10 cigarettes / day.´
- Participation in an interventional study at the time of inclusion.
- Known poor ovarian response in a previous cycle of stimulation (number of oocyte collected ≤ 3, and / or more than 2 previous IVF/ICSI cycles and / or abnormal result in ovarian reserve test (AMH < 1 ng/ml with Immunotech equipment or AMH<0.7 ng/ml with DSL equipment).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Highly purified menotropin (HP-hMG) treatment
Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
|
No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence of moderate/severe OHSS
Tidsramme: 2-12 weeks
|
2-12 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence of each form of OHSS: mild, moderate and severe
Tidsramme: 2-13 weeks
|
2-13 weeks
|
|
Incidence of moderate and of severe OHSS among patients treated by a GnRH agonist or antagonist desensitization protocol
Tidsramme: 2-13 weeks
|
2-13 weeks
|
|
OHSS clinical features description according to the Royal College of Obstetricians and Gynaecologists classification
Tidsramme: 2-13 weeks
|
2-13 weeks
|
|
Patients' baseline characteristics
Tidsramme: At baseline
|
At baseline
|
|
Dosage adjustment, modification of the treatment, coasting and cycle cancellation, no hCG administration and embryo transfer cancellation
Tidsramme: Up to 3 weeks
|
Up to 3 weeks
|
|
Description and duration of hospitalisation, treatments prescribed
Tidsramme: 2-13 weeks
|
2-13 weeks
|
|
Frequency and reasons for stimulation arrest and no embryo transfer decision
Tidsramme: 2-4 weeks
|
2-4 weeks
|
|
Number of oocytes retrieved, number of mature oocytes, fertilization rate, embryo quality, embryo freezing, number and quality of transferred embryos
Tidsramme: 2-3 weeks
|
2-3 weeks
|
|
Description of serious and not serious adverse events
Tidsramme: 2-13 weeks
|
2-13 weeks
|
|
Description of patient's compliance to the prescribed treatment
Tidsramme: 2-4 weeks
|
2-4 weeks
|
|
Clinical pregnancy rate, spontaneous miscarriage and ongoing pregnancy rate
Tidsramme: 4-13 weeks
|
4-13 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 000012
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .